Jamie Arambulo, | |
14010 Vintage Ln, Accokeek, MD 20607-3779 | |
(240) 381-4816 | |
Not Available |
Full Name | Jamie Arambulo |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 14010 Vintage Ln, Accokeek, Maryland |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821402777 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0119006021 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jamie Arambulo, 14010 Vintage Ln, Accokeek, MD 20607-3779 Ph: (240) 381-4816 | Jamie Arambulo, 14010 Vintage Ln, Accokeek, MD 20607-3779 Ph: (240) 381-4816 |
News Archive
A new paper published in the British Dental Journal in May 2020 reports on the new ways of partnership between the dental industry and dental professionals, in view of the extremely high risk of aerosol production during dental procedures, to reduce the risk of passing on COVID-19 infection.
Aria Diagnostics, a molecular diagnostics company, today announced publication of data supporting a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood for evaluation of two common fetal trisomies linked to genetic disorders.
Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.
In research published in the August issue of Free Radical Biology and Medicine, U of T pharmacy and pharmacology professor Peter Wells and his colleagues determined that exposing pregnant mice only once to methamphetamine led to delivery of offspring with long-term neurodevelopmental problems, including reduced motor co-ordination.
Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.
› Verified 9 days ago
Marcia Marie Rosebrock, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2640 Saint Marys View Rd, Accokeek, MD 20607 Phone: 419-487-1590 | |
Teresa Whigham, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2206 Green Ginger Circle, Accokeek, MD 20607 Phone: 301-452-4051 | |
Erika Haley, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 14507 Saint Gregory Way, Accokeek, MD 20607 Phone: 301-882-8511 |